FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							. ,												
1. Name and Address of Reporting Person*						2. Issuer Name <b>and</b> Ticker or Trading Symbol ENANTA PHARMACEUTICALS INC [								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
MELLETT PAUL J														Director			10%	Owner	
(1 +)	- EN	ENTA ]								X	Officer (give title below)			Other (specify below)					
(Last)	3 0	Date of Earliest Transaction (Month/Day/Year)								Treasurer and CFO									
C/O ENANTA PHARMACEUTICALS, INC.						08/14/2014										rreasure	t und Cr O		
500 ARSENAL STREET						33/11/2011													
	ENAL 511	CEE I			4 16	4 If Amendment Date of Original Filed (Month/Day/March)							1,	C. Individual or Jaint/Croup Filing (Charle Assissable					
						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)			NO 450											X Form filed by One Reporting Person					
WATERI	TOWN M	A (	)2472											Form filed by More than One Reporting					
					-										Pers			J J	
(City)	(St	ate) (	Zip)																
		Tabl	e I - N	Non-Deriv	/ative	Sec	uritie	s Ac	auire	ed. Di	sposed o	f. or E	Benefic	ially (	Owne	ed			
																	l	1	
1. Title of S	Security (Inst	r. 3)		2. Transacti Date	on	1 2A. Deemed Execution Date.			3. 4. Securities Acquired (A) or Transaction Disposed Of (D) (Instr. 3, 4 an							ount of	6. Ownership Form: Direct	7. Nature of Indirect	
				(Month/Day	/Year)			e,	Code (Instr.			. 3, 4 anu	Benefi		icially	(D) or Indirect	Beneficial		
						(Month/Day/Year)		'ear)	8)						Owned Following Reported		(I) (Instr. 4)	Ownership (Instr. 4)	
									Code V Amo		Amount	(A) or (D) Price		Trans		action(s)		(111511. 4)	
										ľ	Amount	(D)	11100		(Instr. 3 and 4)				
Common	014				S <sup>(1)</sup>		10,000	D	\$39.12	283(2)		46,397	D						
		Ta	ble II	- Derivat	ive S	ecuri	ities	Acai	uired	. Disr	osed of	or Be	neficial	lv Ov	vned				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of	2.	3. Transaction	3A. De	emed	4.		5. Nu	mber	6. Da	te Exer	cisable and	7. Title	and	8. Pr	ice of	9. Number o	f 10.	11. Nature	
Derivative	Conversion	Date		Execution Date,		ction	n of r. Derivative		Expiration Date (Month/Day/Year)			Amount of Securities		Derivative Security		derivative	Ownership	of Indirect	
Security	or Exercise	(Month/Day/Year)	if any		Code (	Instr.										Securities	Form:	Beneficial	
(Instr. 3) Price of (Month/Day/Year) 8 Derivative Security				ni/Day/Year)	8)	Securities Acquired			Underlying Derivative				(Instr. 5)		Beneficially Owned	Direct (D) or Indirect	Ownership (Instr. 4)		
					(A) or			Security (Instr.				3		Following	(I) (Instr. 4)	(,			
						Disposed of (D) (Instr. 3, 4 and 5)			and 4)						Reported Transaction	(c)			
												(Instr. 4)			(3)				
												╛							
										Amount	7								
													or						
									Date		Expiration		Number of						
					Code	v	(A)	(D)		cisable		Title	Shares						

## **Explanation of Responses:**

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2014 to provide liquidity for tax payments due on account of prior option exercises.
- 2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$38.8100 to \$39.6950, inclusive.

## Remarks:

The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 above.

<u>/s/ Paul J. Mellett</u> <u>08/15/2014</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.